You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Dow
Boehringer Ingelheim
AstraZeneca
Mallinckrodt

Last Updated: April 1, 2020

DrugPatentWatch Database Preview

Litigation Details for Merck & Co. Inc. v. Teva Pharmaceuticals (D. Del. 2004)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Merck & Co. Inc. v. Teva Pharmaceuticals (D. Del. 2004)

Docket   Start Trial Date Filed 2004-08-13
Court District Court, D. Delaware Date Terminated 2006-08-15
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties MERCK & CO. INC.; TEVA PHARMACEUTICALS U.S.A., INC.
Patents 4,621,077; 4,876,248; 4,927,814; 5,358,941; 5,681,590; 5,849,726; 5,994,329; 6,008,207; 6,015,801; 6,090,410; 6,165,513; 6,225,294; 6,432,932; 6,465,443
Attorneys James Walter Parrett , Jr.; Jason C. Abair; Josy W. Ingersoll; Karen Elizabeth Keller; Mary B. Graham; Nicolas G. Barzoukas; Suzy S. Harbison
Firms Deep Ellum Search; Morris, Nichols, Arsht & Tunnell; Shaw Keller LLP; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Merck & Co. Inc. v. Teva Pharmaceuticals
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Merck & Co. Inc. v. Teva Pharmaceuticals
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for Merck & Co. Inc. v. Teva Pharmaceuticals (D. Del. 2004)

Date Filed Document No. Description Snippet Link To Document
2005-03-08 11 MEMORANDUM in Support Action No. 04-939: U.S. Patents 5,994,329, 6,432,932, and 6,465,443. These patents include claims for once-weekly…the patents listed in the FDA’s “Orange Book” in connection With that drug, or that those patents are …of bone. The patents listed in the Orange Book for Actonel include P&G’s U.S. Patent 5,583,l22, Which…addition to the ’ l22 patent, the Orange Book also lists for Actonel three patents belonging to Merck, …cases the patents claim risedronate or its use. P&G has a legal interest in all the patents in both External link to document
2004-08-13 2 Patent/Trademark Report to Commissioner Report to Commissioner of Patents and Trademarks. Exit original. Re: 5,994,329; 6,432,932 B1; 6,465,443…2004 15 August 2006 1:04-cv-00939 830 Patent None District Court, D. Delaware External link to document
2005-08-18 34 Notice (Other) All documents that refer or relate to U.S. Patents 5,994,329, 6,015_,801_, 6,225,294, 6,432,932 and 6,465,443…respect to obtaining any rights under U.S. Patents 5,994,329, 6,015,801, 6,225,294, 6,432,932 and 6,465,443…to the validity or enforceability of U.S. Patents 5,994,329, 6,015,801, 6,225,294, 6,432,932 and 6,465,443…anyone on its behalf With respect to U.S. Patcnts 5,994,329, 6,015,801, 6,225,294, 6,432,932 and 6,465,443…2004 15 August 2006 1:04-cv-00939 830 Patent None District Court, D. Delaware External link to document
2005-10-25 38 Notice of Service .S. Patents 5,994,329, 6,015,801, 6,225,294, 6,432,932 and 6,465,4.43, or any other Merck Patents. Case…behalf with respect to U.S. Patcnts 5,994,329, 6,015,801, 6,225,294, 6,432,932 and 6,465,443 or any ofthem…2004 15 August 2006 1:04-cv-00939 830 Patent None District Court, D. Delaware External link to document
2005-10-27 43 Notice (Other) OF TOPICS l. For each claim of U.S. Patent 5,994,329, 6,432,932, and 6,465,443 Which Merck asserts is…properties 2. For each claim of U.S. Patent 5,994,329, 6,432,932, and 6,465,443 vvhich l\/lerck asserts…2004 15 August 2006 1:04-cv-00939 830 Patent None District Court, D. Delaware External link to document
2006-06-09 60 Opening Brief in Support The two patents in suit are Merck’s United States Patent Nos. 5,994,329 (the “’329 patent”) and 6,432,932…November 30, 1999, United States Patent No. 5,994,329 (the “’329 patent”) issued to Anastasia G. Daifotis…6,432,932 (the “’932 patent”) (collectively, “Merck’s patents”). The ’329 patent is attached as Exhibit…13” of Teva’s U.S. Patent No. 6,476,006 (the “’006 patent”). The ’006 patent contains a mere eight…of bisphosphonates covered by Merck’s patents. Under the patent license from Merck, P&G launched External link to document
2006-06-09 62 Exhibit S-T to expire on August 14, 2018. (PTX 4,621,077. Cited. 1). …evidence. 6. Patents O314(5) The first step in any patent invalidity 13. Patents O101(2) …as a patent. 37 C.F.R. § 1.56(a). 23. Patents O97 29. Patents O97…the patent application. 37 C.F.R. § 1.56(a). 30. Patents O97 24. Patents O97…against competitor, alleging that its patent the ’259 patent by KLA’s SP1–TBI External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
McKesson
AstraZeneca
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.